Patent intelligence · US
US 11034672
Tyrosine kinase inhibitor compositions, methods of making and methods of use
Tyrosine kinase inhibitor compositions, methods of making and methods of use
Patent details — US 11034672
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 15, 2021
- Expiration
- Jun 10, 2041
- Applicant
- Black Diamond Therapeutics, Inc.
- Claims
- 29
- CPC classes
- A61P, A61P35/00
Quick answer
US 11034672 (Tyrosine kinase inhibitor compositions, methods of making and methods of use) is held by Black Diamond Therapeutics, Inc.. Status: granted. Granted Jun 15, 2021. Expires Jun 10, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Black Diamond Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 29
- CPC classes
- A61P, A61P35/00
More from Black Diamond Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12343394
CD38 modulating antibody agents
granted -
US 12325699
Antibacterial compounds
granted -
US 12304964
CD38 modulating antibody
granted -
US 12187754
LpxC inhibitors and uses thereof
granted -
US 12161717
CD38 modulating antibody agents
granted -
US 12162949
CD38 antibody
granted -
US 11897873
Kappa opioid receptor antagonists and products and methods related thereto
granted -
US 11780930
CD38 modulating antibody
granted
Frequently asked questions
What is US patent 11034672?
US 11034672 (Tyrosine kinase inhibitor compositions, methods of making and methods of use) is held by Black Diamond Therapeutics, Inc.. Status: granted. Granted Jun 15, 2021. Expires Jun 10, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11034672?
Black Diamond Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 38 pharmaceutical patents for this assignee.
When does US 11034672 expire?
Our index shows an expiration date of Jun 10, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.